bioihbjkbjnl/mcl2 huggingface dataset:
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Condition: Bacterial Infections; Acute Bacterial Skin and Skin Structure Infection
MeSH terms: Infections; Communicable Diseases; Bacterial Infections; Skin Diseases, Bacterial
Intervention: Dalbavancin; Usual Care
Intervention description: Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.; Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Intervention MeSH terms: Dalbavancin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 91.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Critical Pathways; Health Facilities; Clinical Protocols; Patient Satisfaction; Absenteeism; Anti-Bacterial Agents; Quality of Life; Economics, Medical; Health Resources; Health resource utilization; Acute bacterial skin and skin structure infection (ABSSSI)

Summary:

      The purpose of this study is to assess the effect of a new critical pathway (use of
      guideline-based patient identification criteria and for those who meet these criteria, use of
      dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin
      Structure Infections)
    

Eligibility criteria:

        Inclusion Criteria:

          -  Admitted patients who meets the clinical definition for Acute Bacterial Skin and Skin
             Structure Infections (ABSSSI)

          -  Known or suspected gram-positive infection.

        Exclusion Criteria:

          -  Known or suspected gram-negative infections, anaerobic infections, or fungemia

          -  Known or suspected infections that are severe, life threatening or are not included in
             the ABSSSI Food and Drug Administration (FDA) guidance

          -  Injection drug users with a fever

          -  Severe neurological disorder leading to immobility or confined to a wheelchair

          -  Bilateral Lower extremity involvement of the suspected infection.
Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis
Condition: Interstitial Cystitis
MeSH terms: Cystitis; Cystitis, Interstitial
Intervention: Oxytocin; Saline as a nasal spray
Intervention description: A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.; A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
Intervention MeSH terms: Oxytocin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 25.0
Sex: All
Minimum age: 19 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Interstitial cystitis (IC); Oxytocin; Bladder; Void

Summary:

      Anecdotal evidence suggests female patients with painful bladder disorder interstitial
      cystitis (IC) can experience a significant attenuation of their systems while breastfeeding.
      Since it has been shown that postpartum lactation is a time associated with decreased levels
      of stress, and stress has been shown to exacerbate IC-related pain, the investigators have
      developed an interest in the effects of the hormones involved in postpartum lactation on
      stress and pain. Based on a series of pre-clinical experiments, the investigators believe the
      hormone oxytoxin has both analgesic and anxiolytic properties which make it a potentially
      useful agent for the treatment of stress-exacerbated chronic pain syndrome such as IC.
      Therefore, the investigators propose a double-blinded, placebo-controlled crossover trial of
      intranasal oxytocin vs. intranasal saline for bladder pain in a cohort of patients with IC
      and some degree of continuous, daily pain.
    

Eligibility criteria:

        Inclusion Criteria:

          -  19 - 65 years of age

          -  Must meet the current National Institute of Diabetes and Digestive and Kidney Diseases
             (NIDDK) diagnostic criteria for interstitial cystitis and have some degree of
             continuous daily pain

        Exclusion Criteria:

          -  Pregnancy

          -  Under the age of 19

          -  Older that the age of 65

          -  Breastfeeding women

          -  Uncontrolled hypertension

          -  History of significant cardiac or pulmonary disease (including arrhythmias)

          -  Known allergy to oxytocin

          -  Severe psychiatric disease

          -  Patients who have undergone procedural interventions within the past month related to
             their interstitial cystitis